ArticleDisease markers2017
Potential Hepatoprotective Role of Galectin-3 during HCV Infection in End-Stage Renal Disease Patients.
Article in Disease markers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Exploring the impact of galectins on liver cancer: From immunopathogenesis to potential targets.World journal of gastroenterology · 2025Review
- Plasma levels of soluble PD-1, TIM-3, LAG-3 and galectin-3 and the degree of liver fibrosis in CHC and the impact of successful antiviral treatment on their levels.Scientific reports · 2025Article
- The Pivotal Role of Galectin-3 in Viral Infection: A Multifaceted Player in Host-Pathogen Interactions.International journal of molecular sciences · 2023Review
- Galectin-3 as an important prognostic marker for COVID-19 severity.Scientific reports · 2023Article
- Potential Protective Role of Galectin-3 in Patients with Gonarthrosis and Diabetes Mellitus: A Cross-Sectional Study.International journal of environmental research and public health · 2022Article
- Role of Galectins in the Liver Diseases: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Article
- Evaluation of Serum and Gene Expression of Galectin-4, Interleukin-27, and Complement-7 in Hepatitis C Virus-Infected Egyptian Patients.BioMed research international · 2020Article
- Metabolic syndrome attenuates ulcerative colitis: Correlation with interleukin-10 and galectin-3 expression.World journal of gastroenterology · 2019Article
- Galectin-3 Deficiency Facilitates TNF-α-Dependent Hepatocyte Death and Liver Inflammation in MCMV Infection.Frontiers in microbiology · 2019Article
- Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma.Mediators of inflammation · 2018Article
- Comparison of diagnostic performance of transcription-mediated amplification with chemiluminescent microparticle immunoassay in the detection of hepatitis C virus in dialysis patient group.Asian journal of transfusion scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus infection (HCV), one of the greatest causes of liver disease, is a frequent complication in patients with end-stage renal disease (ESRD) on dialysis. ESRD is defined as decreased glomerular filtration and also accompanied by impaired function of the immune system. Galectin-3 is a
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.